attempt
transmit
felin
malign
lymphoma
mice
murin
hepat
viru
mhv
accident
recov
convent
rear
swiss
mice
receiv
prolong
treatment
antilymphocyt
serum
mice
viru
requir
concomit
infect
eperythrozoon
coccoid
produc
diseas
test
antibodi
varieti
virus
perform
serum
control
coloni
mice
mice
recov
experiment
infect
well
serum
pool
flom
vaccin
nonvaccin
mice
challeng
recov
agent
antibodi
mhv
complement
fix
cf
antigen
demonstr
last
mention
serum
mice
harbour
hepat
viru
may
thu
toler
cf
antigen
situat
analog
oneornaviru
infect
natur
host
liver
patholog
confluent
focaltyp
necrosi
resembl
produc
certain
mhv
strain
label
newli
isol
viru
mhv
swisscap
town
abbrevi
mhv
sct
immunodepress
antilymphocyt
serum
al
document
caus
latent
virus
manifest
anim
alliso
report
work
oncogenesi
alstreat
mice
develop
hepat
consid
probabl
result
potenti
pathogen
effect
mild
strain
mhv
immunosuppress
purpos
commun
record
accident
recoveri
murin
hepat
viru
mhv
mice
convent
rear
stock
receiv
prolong
treatment
al
attempt
transmit
felin
malign
lymphoma
addit
serial
transmit
diseas
document
serolog
find
swiss
albino
mice
obtain
convent
rear
coloni
univers
cape
town
medic
school
rabbit
antimousedymphocyt
serum
prepar
accord
twopuls
procedur
levey
mm
awaa
assay
immunodepress
potenc
bacteriolog
tissu
ascit
fluid
examin
microscop
use
standard
procedur
cultur
aerob
anaerob
bacteria
myeoplasma
tissu
light
microscopi
fix
formaldehyd
solut
per
cent
formalin
section
stain
haematoxylineosin
blood
smear
liver
imprint
prepar
stain
either
giemsa
leishman
stain
serum
sampl
sent
microbiolog
associ
inc
bethesda
usa
antibodi
test
differ
virus
includ
mhv
recommend
firm
viru
screen
experiment
mice
fresh
mous
liver
tissu
infect
isol
agent
eighth
murin
passag
ground
tenbrock
grinder
suspend
wv
pb
contain
iu
penicillin
yg
streptomycin
per
ml
suspens
lightli
centrifug
formalin
ad
supernat
fluid
give
per
cent
final
concentr
materi
held
c
week
prior
use
vaccin
attempt
transmit
malign
felin
lymphoma
mice
small
fresh
piec
lymphomat
spleen
cat
implant
subcutan
group
old
mice
immedi
thereaft
mous
inject
intraperiton
ml
al
repeat
second
fourth
day
thereaft
dose
al
reduc
ml
administ
via
rout
everi
day
thirti
five
day
commenc
experi
moribund
mous
observ
kill
autopsi
found
emaci
liver
enlarg
capsular
cut
surfac
show
presenc
multipl
yellowish
necrot
loci
vari
size
less
mm
mm
diamet
strawcolour
asciti
fluid
macroscop
featur
note
organ
bacteriolog
examin
reveal
coliform
organ
periton
fluid
otherwis
complet
neg
diseas
first
transmit
experiment
nonal
treat
mice
use
wv
pool
organ
suspens
liver
kidney
spleen
pb
contain
iu
penicillin
zg
streptomycin
per
ml
suspens
held
c
day
prior
inject
ml
amount
intraperiton
mous
diseas
serial
transmit
time
mice
vari
age
intraperiton
inject
either
infect
liver
liver
plu
spleen
suspens
pb
antibiot
incident
transmiss
diseas
also
achiev
use
either
serum
blood
clot
suspens
spleen
suspens
infect
mice
oxytetracyclin
treatment
liver
suspens
diseas
mice
destroy
infect
mice
see
furthermor
infecti
agent
pass
pore
diamet
swinnex
millipor
filter
millipor
corp
bedford
mass
usa
observ
made
routin
transmiss
diseas
indic
younger
mice
suscept
older
one
addit
certain
litter
resist
other
reflect
genet
differ
randomli
bred
stock
well
possibl
differ
immun
statu
eg
passiv
acquir
immun
mother
larg
dose
infecti
materi
inject
intraperiton
mice
vari
age
day
clinic
diseas
first
observ
day
later
one
occas
passag
agent
staphylococcu
pseudomona
aeruginosa
cultur
liver
clostridium
bi
ermentan
spleen
mous
hepat
howev
occas
bacteriolog
examin
either
singl
pool
liver
mice
suffer
liver
diseas
conduct
bacteria
isol
mycoplasma
organ
isol
diseas
liver
blood
smear
liver
imprint
smear
control
mice
breed
coloni
mice
inject
day
previous
heart
blood
coloni
mice
mice
suffer
sever
experiment
induc
hepat
fail
reveal
evid
e
coccoid
cours
diseas
alter
addit
high
concentr
oxyetracyclin
infecti
materi
pool
serum
sampl
sent
microbiolog
associ
inc
first
kill
control
mice
either
sex
coloni
contain
haemagglutinationinhibit
hi
antibodi
titr
theiler
encephalomyel
viru
gd
vii
minut
viru
mice
mvm
neg
antibodi
virus
second
serum
pool
femal
weanl
mice
bled
week
recoveri
experiment
infect
subleth
concentr
infecti
materi
reveal
antibodi
test
virus
third
combin
serum
pool
batch
mice
initi
vaccin
intraperiton
either
ml
vaccin
week
age
subsequ
challeng
day
later
infecti
materi
via
rout
well
batch
femal
surviv
inject
infecti
materi
without
first
vaccin
pool
h
antibodi
titr
pneumonia
viru
mice
pvm
mhv
complement
fix
antibodi
titr
neg
antibodi
virus
mice
suffer
experiment
induc
lesion
kill
obvious
ill
macroscop
featur
autopsi
ident
describ
mous
isol
made
name
variabl
amount
ascit
fluid
pale
loci
necrosi
liver
fig
microscop
examin
fig
ous
liver
autopsi
show
multipl
pule
ecrot
loci
liver
show
irregular
area
coagul
necrosi
usual
involv
part
lobul
often
extend
adjac
lobul
confluent
necrosi
fig
necrot
area
randomli
distribut
within
lobnl
lobul
abut
central
vein
other
periport
locat
necrosi
associ
patchi
mononuclear
cell
infiltr
lymphocyt
maerophag
predomin
moder
number
mitot
figur
note
within
parenchym
cell
indic
attempt
regener
fig
viral
inclus
bodi
seen
routin
section
organ
show
featur
note
n
attempt
transmit
felin
malign
lymphoma
mice
receiv
treatment
al
one
anim
unexpectedli
develop
fulmin
hepat
diseas
readili
transmiss
nonal
treat
mice
mean
serum
organ
suspens
inect
anim
date
passag
serial
time
believ
caus
agent
viru
pass
millipor
filter
resist
sever
antibodi
includ
tetracyclin
murin
hepat
viru
cf
antibodi
detect
serum
pool
nonvaccin
vaccin
mice
challeng
isol
agent
pattern
confluent
zonal
necrosi
associ
round
cell
infiltr
liver
resembl
produc
mhv
strain
quit
unlik
pyogen
lesion
would
expect
bacteri
infect
cultur
diseas
liver
bacteria
includ
mycoplasma
neg
sever
occas
detect
mhv
cf
antibodi
well
local
diseas
liver
would
suggest
viru
mhv
strain
virus
antibodi
demonstr
known
caus
murin
hepat
design
strain
mhv
mhv
swisscap
town
abbrevi
mhv
sct
strain
miiv
requir
coinfect
host
e
coccoid
order
express
pathogen
evid
found
e
coccoid
univers
cape
town
coloni
addit
e
coccoid
known
highli
suscept
tetracyclin
yet
present
studi
lesion
still
produc
follow
treatment
infecti
materi
oxytetracyclin
thu
mhv
sct
least
swiss
mice
capabl
produc
hepat
independ
e
coecoid
variabl
result
obtain
serolog
screen
test
virus
conduct
serum
pool
indic
shortcom
test
determin
viru
statu
stock
laboratori
mice
serial
passag
organ
materi
combin
frequent
serolog
test
would
reliabl
failur
detect
cf
antibodi
mhv
serum
sampl
either
control
mice
mice
recov
hepat
could
result
inadequ
sensit
test
altern
mice
may
toler
cf
antigen
situat
analog
toler
display
anim
homolog
group
specif
oncornaviru
antigen
may
relev
connect
coronavirus
way
resembl
oncornavirus
latter
hypothesi
correct
presenc
cf
antibodi
serum
pool
challeng
nonvaccin
vaccin
mice
could
attribut
abrog
toler
vaccin
mice
formalin
modifi
antigen
termin
toler
relat
modifi
antigen
well
recogn
phenomenon
appear
diseas
mous
agent
recov
could
result
viral
activ
secondari
stress
caus
frequent
treatment
al
altern
viral
activ
may
result
specif
depress
immun
al
even
mice
latent
infect
mhv
toler
cf
antigen
seem
like
mechan
format
neutral
antibodi
viru
cell
mediat
immun
phagocytosi
interferon
product
exist
maintain
hostparasit
equilibrium
prevent
develop
overt
diseas
lecoveri
latent
infect
mice
follow
moder
superinfect
may
result
enhanc
abovement
mechan
mice
latent
infect
mhv
thu
appear
state
delic
hostparasit
equilibrium
depend
varieti
factor
similar
complic
interplay
factor
probabl
also
respons
sporad
occurr
unpredict
cours
hepat
lower
anim
man
also
rais
possibl
develop
viru
hepat
man
receiv
al
antilymphocyt
globulin
alg
evan
etal
report
liver
damag
patient
follow
immunosuppress
therapi
patient
treatment
includ
administr
alg
consid
hepatotox
drug
viru
hepat
cytomegaloviru
possibl
caus
factor
recent
case
document
associ
immunosuppress
therapi
hepat
presenc
hepat
b
antigen
human
patient
